Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

References

• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
   PubMed Web of Science ®Google Scholar
• SAXENDA (liraglutide) injection prescribing information. 2020 [cited 2021 Apr 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf
   Google Scholar
• Saxenda summary of product characteristics. 2021 [cited 2021 Apr 21] Available from: https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf
   Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413.
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
   PubMed Web of Science ®Google Scholar
• WEGOVY (semaglutide) injection prescribing information. 2021 [cited 2021 Jun 9] Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
   Google Scholar
• Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211–R234.
   PubMed Web of Science ®Google Scholar
• Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875–E891.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, and Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
   PubMed Web of Science ®Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424.
   PubMed Web of Science ®Google Scholar
• Gill L, Mackey S. Obstetrician-gynecologists‘ strategies for patient initiation and maintenance of antiobesity treatment with glucagon-like peptide-1 receptor agonists. J Womens Health (Larchmt). 2021;30(7):1016–1027.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–347.
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286.
   PubMed Web of Science ®Google Scholar
• Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:1–15.
   Web of Science ®Google Scholar
• Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885–R895.
   PubMed Web of Science ®Google Scholar
• Thazhath SS, Marathe CS, Wu T, et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes. 2016;65(1):269–275.
   PubMed Web of Science ®Google Scholar
• Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323.
   PubMed Web of Science ®Google Scholar
• Gautier JF, Martinez L, and Penfornis A, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice--EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2015;32(9):838–853.
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–412.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• Wharton S, Haase CL, Kamran E, et al. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obes Sci Pract. 2020;6(4):439–444.
   PubMed Web of Science ®Google Scholar
• Almandoz JP, Lingvay I, Morales J, et al. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390–402.
   PubMedGoogle Scholar
• Jain Ab, Ali A, Gorgojo Martínez JJ, et al. Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract. 2021;75(2):e13731.
   PubMed Web of Science ®Google Scholar